ANSES DG Delegates Signature Authority: Streamlined Regulatory Processing Expected
ANSES's Director General has formally delegated signature authority to the General Secretariat, effective 27 August 2026. This move aims to expedite administrative processes for health product authorisations and regulatory compliance decisions, impacting manufacturers seeking market approval in France.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Paris, France — 31 August 2026. The Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES) has formally announced Decision N° 2026-142, effective 27 August 2026. This decision delegates signature authority from the agency's Director General to the General Secretariat. The primary objective is to streamline and accelerate the administrative processing of regulatory files, including those pertaining to food supplements and health products under ANSES's remit.
Historically, bottlenecks in signature workflows have contributed to extended review periods for ingredient authorisations, novel food applications, and health claim dossiers. This delegation signifies a strategic internal reorganisation designed to enhance operational efficiency. Supplement manufacturers operating in or planning to enter the French market should interpret this as a clear signal from ANSES regarding its commitment to faster, yet rigorous, regulatory oversight. The move could particularly benefit dossiers requiring multiple rounds of expert review and final administrative approval.
For operators, the practical implication is a potential reduction in the administrative phase of the regulatory journey. While scientific assessment timelines remain subject to expert panel workloads, the finalisation and official communication of decisions are expected to accelerate. This will enable brand owners to gain clarity on market access or reformulation requirements more rapidly, allowing for quicker adaptation to regulatory directives and more predictable product launch schedules. Manufacturers should ensure their submission dossiers are meticulously prepared to capitalise on these expedited processes, as swift rejection for incomplete applications would negate any time-saving benefits.
What this means for France
French supplement manufacturers and brand owners should prepare for potentially compressed regulatory timelines. This delegation could shorten the administrative finalisation of Novel Food authorisations, such as for CBD or specific botanicals, by several weeks. Procurement leads must align with R&D to ensure raw material sourcing and formulation capabilities can respond quickly to ANSES’s faster feedback. Brands with existing dossiers under review could see their compliance confirmations issued earlier, enabling an expedited Q4 2026 product launch. The change also enhances France's position as a market where regulatory clarity, once achieved, translates faster into commercial operations, incentivising precise initial submissions.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.